发明名称 |
TREATMENT OF HEPATITIS C INFECTION WITH METALLOPORPHYRINS |
摘要 |
<p>The present invention is directed to the treatment of hepatitis C infection with a metalloporphyrin. In particular, the present invention is based on the discovery that the NS5A protein plays a key role in HCV RNA replication by participating in polyprotein cleavage, interferon response and cellular signaling pathways. It has been found that metalloporphyrins, such as zinc porphyrins, induce post-translational down-regulation of HCV NS5A protein in an ubquitin-proteasome degradation pathway. That is, metal loporphyrins can be used to activate the ubiquitin-proteasomal pathway of NS5A protein catabolism. As a result, metal loporphyrins can be used to significantly suppress HCV viral replication in HCV infected cells.</p> |
申请公布号 |
WO2010040063(A1) |
申请公布日期 |
2010.04.08 |
申请号 |
WO2009US59395 |
申请日期 |
2009.10.02 |
申请人 |
THE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS MEDICAL CENTER;BONKOVSKY, HERBERT, L.;HOU, WEIHONG |
发明人 |
BONKOVSKY, HERBERT, L.;HOU, WEIHONG |
分类号 |
A01N43/04;A61K31/70 |
主分类号 |
A01N43/04 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|